LY2181308

Gataparsen

Gataparsen

Add article description

Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

Quick Facts Clinical data, Other names ...

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References

  1. [1]
    Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. (August 2011). "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (2): 505–11. doi:10.1007/s00280-010-1506-7. PMID 21079959.
  2. [2]
    "Search of: LY2181308". ClinicalTrials.gov.
  3. [3]
    "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31.
  4. [4]
    "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
  5. [5]
    "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
  6. [6]
    "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article LY2181308, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.